Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Sales update soon?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1410)
•••
Comment by GrahamBon Nov 13, 2023 7:42pm
71 Views
Post# 35733223

RE:RE:RE:RE:Sales update soon?

RE:RE:RE:RE:Sales update soon?
MartyD wrote: Good for you.  Based on what your investment criteria is, you should not even be following this stock. 

Thanks for the advice_I am good figuring out how, when, and where to direct my energy and capital.

It was promoted to me, and I did the work so its easy to follow now.
You have to turn over a lot of stones with small caps, to find a winner, There are about 25 I follow.
If things continue along and they continue to not make sales-so be it.
If they suprise and actually get traction-I will be there to jump in.
Now while I am sure discussing each others approaches is riveting...
Now lets get back to talking about the company.
How many sales do you expect in q3? Q4?
Do you think the predicted "flood" of sales is going to happen?
The market has been voting
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities